A groundbreaking, twice-yearly injection for HIV prevention is hailed as a potential ‘game-changer’. However, it is at the centre of a fierce debate regarding affordability. Health activists worldwide implore its manufacturer, Gilead Sciences, to prevent a “missed opportunity for achieving equity.” This twice-yearly HIV jab could revolutionise prevention efforts. But that will only occur if it becomes accessible to all.…
Tag: Health Justice Initiative
-
Competition Commission probes insulin price fixing
The Competition Commission in South Africa has launched a formal investigation into leading insulin manufacturers Novo Nordisk and Sanofi Aventis following serious allegations of anti-competitive conduct. The inquiry was initiated after health activists complained about Novo Nordisk’s decision to cease supplying human insulin pens to the country’s Health Department in 2024. This move has forced thousands of diabetic patients to…